Skip to content

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.5×0.0×
Exelixis logo
ExelixisEXEL
0.9×+0.1×
CG Oncology logo
CG OncologyCGON
0.0×
Lantheus Holdings logo
Lantheus HoldingsLNTH
0.7×-0.1×

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's asset turnover?
Tango Therapeutics (TNGX) reported asset turnover of 0.2× in Q1 2026.
How has Tango Therapeutics's asset turnover changed year-over-year?
Tango Therapeutics's asset turnover increased by 33.2% year-over-year, from 0.1× to 0.2×.
What is the long-term trend for Tango Therapeutics's asset turnover?
Over 4 years (2021 to 2025), Tango Therapeutics's asset turnover has grown at a 13.6% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.